Ishares Diversified Alternatives Trust (AMEX:ALT)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Ishares Diversified Alternatives Trust Charts. Click Here for more Ishares Diversified Alternatives Trust Charts.](/p.php?pid=staticchart&s=A%5EALT&p=8&t=15)
Alteon to Present at the Rodman & Renshaw Techvest 2nd Annual
Global Healthcare Conference
- Presentation to be Webcast -
PARSIPPANY, N.J., April 19 /PRNewswire-FirstCall/ -- Alteon Inc. (AMEX:ALT)
announced today that Kenneth I. Moch, President and Chief Executive Officer,
will participate in the Rodman & Renshaw Techvest 2nd Annual Global Healthcare
Conference in Paris. Mr. Moch is scheduled to present on Wednesday, May 4,
2005 at 3:30 pm (9:30 am, ET). The presentation will be webcast and accessible
at Alteon's website, http://www.alteon.com/ .
Note to Conference Attendees: Alteon has made time available for one-on- one
meetings at the conference. Please contact the one-on-one conference desk or
contact Susan Pietropaolo directly if you are interested in setting up a
meeting.
About Alteon
Alteon is developing several new classes of drugs that have shown the potential
to reverse or slow down diseases of aging and complications of diabetes. These
compounds appear to have an impact on a fundamental pathological process caused
by the progressive formation of protein-glucose complexes called Advanced
Glycation End-products (A.G.E.s). The formation and crosslinking of A.G.E.s
lead to a loss of flexibility and function in body tissues and organs and have
been shown to be a causative factor in many age- related diseases and diabetic
complications. Alteon has created a library of novel classes of compounds
targeting the A.G.E. pathway.
Alteon's lead compound alagebrium chloride (formerly ALT-711), the only A.G.E.
Crosslink Breaker in advanced human testing, has demonstrated safety and
efficacy in several Phase 2 trials and is being developed for systolic
hypertension, heart failure and erectile dysfunction. Approximately 1,300
patients have been involved in alagebrium's human clinical trials to date, of
whom approximately 1,000 have received active compound. Clinical studies of
alagebrium include the Phase 2b systolic hypertension trial, SPECTRA (Systolic
Pressure Efficacy and Safety Trial of Alagebrium), the Phase 2a heart failure
study, PEDESTAL (Patients with Impaired Ejection Fraction and Diastolic
Dysfunction: Efficacy and Safety Trial of ALagebrium), the Phase 2a EMERALD
study (Evaluation of Alagebrium in Erectile Dysfunction in Diabetic Males on
PDE5 Inhibitors), as well as a fourth study exploring mechanism of action in
endothelial dysfunction.
In February 2005, Alteon voluntarily and temporarily suspended enrollment of
new patients into the Company's ongoing alagebrium clinical studies pending
receipt of additional pre-clinical data, which are expected by mid-year 2005.
The Company expects that decisions regarding resumption of enrollment will be
made at that time.
For more detailed information about alagebrium, please visit the scientific
publications section of the Alteon website, http://www.alteon.com/ .
Any statements contained in this press release that relate to future plans,
events or performance are forward-looking statements that involve risks and
uncertainties including, but not limited to, those relating to technology and
product development (including the possibility that early clinical trial
results may not be predictive of results that will be obtained in large-scale
testing or that any clinical trials will not demonstrate sufficient safety and
efficacy to obtain requisite approvals or will not result in marketable
products), regulatory approval processes, intellectual property rights and
litigation, competitive products, ability to obtain financing, and other risks
identified in Alteon's filings with the Securities and Exchange Commission. The
information contained in this press release is accurate as of the date
indicated. Actual results, events or performance may differ materially. Alteon
undertakes no obligation to publicly release the result of any revision to
these forward-looking statements that may be made to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events.
DATASOURCE: Alteon Inc.
CONTACT: Susan M. Pietropaolo, Director, Corporate Communications &
Investor Relations of Alteon Inc., +1-201-818-5537 dir.,
Web site: http://www.alteon.com/